American Journal of Cardiovascular Drugs

, Volume 5, Issue 4, pp 225–231

Therapeutic Potential of Monteplase in Acute Myocardial Infarction

  • Teruo Inoue
  • Ryoichi Nishiki
  • Manabu Kageyama
  • Koichi Node
Leading Article

DOI: 10.2165/00129784-200505040-00002

Cite this article as:
Inoue, T., Nishiki, R., Kageyama, M. et al. Am J Cardiovasc Drugs (2005) 5: 225. doi:10.2165/00129784-200505040-00002

Abstract

Thrombolysis with conventional thrombolytic agents prior to percutaneous coronary intervention (PCI) has had no impact on the treatment of acute myocardial infarction (AMI). However, the development of mutant tissue type plasminogen activators (mt-PA) has prompted us to reassess the combination of thrombolysis and PCI. Monteplase is a newly developed mt-PA that can be administered as a single intravenous bolus injection. The results of the COMA (COmbining Monteplase with Angioplasty) trial, suggest that monteplase administration prior to emergent PCI in AMI improves 6-month outcomes and possibly the long-term prognosis of myocardial infarction. Combining monteplase administration on presentation at a community hospital with prompt transfer to a tertiary center for PCI would be an ideal strategy for the treatment of AMI.

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Teruo Inoue
    • 1
  • Ryoichi Nishiki
    • 2
  • Manabu Kageyama
    • 3
  • Koichi Node
    • 1
  1. 1.Department of Cardiovascular and Renal MedicineSaga University Faculty of MedicineSagaJapan
  2. 2.Pharmaceuticals DepartmentEisai Co. LtdTokyoJapan
  3. 3.Product Planning DivisionEisai Co. LtdTokyoJapan